Futibatinib
Sign in to save this workspacePrimary targets: FGFR2 · FDA status: FDA Approved
Selectivity scorecard
KISS
98.48
Gini
0.718
CATDS
0.032
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Futibatinib. Strongest target: FGFR2 at 99.3% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | FGFR2 | 99.3% | 0.7% |
| 2 | FGFR3 | 99.0% | 1.0% |
| 3 | FGFR1 | 99.0% | 1.0% |
| 4 | FGFR4 | 97.9% | 2.1% |
| 5 | RET | 97.7% | 2.3% |
| 6 | BMX_ETK | 95.2% | 4.8% |
| 7 | FGR | 81.5% | 18.5% |
| 8 | JAK2 | 81.4% | 18.6% |
| 9 | TRKC | 78.4% | 21.6% |
| 10 | YES_YES1 | 70.3% | 29.7% |
| 11 | TRKB | 65.5% | 34.5% |
| 12 | JAK1 | 64.4% | 35.6% |
| 13 | MKK7 | 60.4% | 39.6% |
| 14 | ROS_ROS1 | 58.1% | 41.9% |
| 15 | DDR1 | 56.4% | 43.6% |
| 16 | CK1EPSILON | 54.8% | 45.2% |
| 17 | ZAP70 | 46.1% | 53.9% |
| 18 | BLK | 42.6% | 57.4% |
| 19 | FLT4_VEGFR3 | 41.8% | 58.2% |
| 20 | FLT3 | 32.8% | 67.2% |
Selectivity landscape
Where Futibatinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Futibatinib.
Annotations
Sign in to read and post annotations.
Loading…